CRISPR Therapeutics (CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior successes to become a biotech powerhouse and prove to investors that it isn't a one-trick pony.The next three years will be critical for both of those things. Here's what to expect.This bird is leaving the nestBy late 2027, CRISPR will be a larger biotech, with much more revenue, more collaborators, and a much bi ...